Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 20 от 154

Набира участници Фаза 1/2

A Study of LM-350 in Subjects With Advanced Solid Tumours

Malignant Tumors

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

Начало: 28.08.2025 Край: 30.06.2030 Възраст: от 18 г. Лечение

Australia, China LaNova Medicines Limited NCT07112222

Набира участници Фаза 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

KCNT1-Related Epilepsy

This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.

Начало: 28.08.2025 Край: 01.03.2026 Възраст: 18–55 г. Лечение

Australia Actio Biosciences, Inc. NCT07156201

Набира участници Фаза 1

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

Healthy

This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants. The primary aim of this study is to assess the impact of food and rabeprazole co-administration on the systemic exposure of VRN110755. Safety and tolerability will also be evaluated.

Начало: 27.08.2025 Край: 30.01.2026 Възраст: 18–65 г. Лечение

Australia Voronoi, Inc NCT07141381

Набира участници

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

Allergic Asthma Thunderstorm Asthma Seasonal Allergic Rhinitis Grass Pollen Allergy +2

Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.

Начало: 27.08.2025 Край: 31.12.2030 Възраст: 18–70 г. Диагностика

Australia University of Melbourne NCT07055542

Набира участници Фаза 1/2

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Advanced Solid Tumor

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

Начало: 27.08.2025 Край: 01.08.2028 Възраст: от 18 г. Лечение

Australia, China BioNTech SE NCT07147348

Набира участници Фаза 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Acute Gouty Arthritis Gout Flare Gout Flares Acute Gout Flare

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Начало: 26.08.2025 Край: 01.06.2026 Възраст: 18–70 г. Лечение

Australia, China, United States Atom Therapeutics Co., Ltd NCT07145229

Набира участници Фаза 1

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Solid Tumors MTAP-deleted Solid Tumors MTAP Deletion

This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion. The study will be conducted in three parts, with Part 1 currently open for enrollment. The primary objectives of the study are to: * Evaluate the safety and tolerability of PEP08, PK and PD * Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) * Assess preliminary signs of anti-tumor activity of PEP08 Key study questions include: * What is the recommended dose of PEP08 for further development? * Wht is the tolerable dose of PEP08 when administered alone or in combination? * Does PEP08 show early evidence of clinical activity in patients with MTAP-deleted tumors? Participants in the study will: * Receive PEP08 alone or in combination with another anti-cancer agent, depending on the study part * Attend regular clinic visits for treatment administration, laboratory assessments, and tumor evaluations * Be enrolled in one of the following study phases over time: * \- Part 1: Monotherapy dose escalation (currently enrolling). * \- Parts 2 and 3 (monotherapy extension and combination therapy) will be activated in future protocol amendments.

Начало: 26.08.2025 Край: 01.03.2028 Възраст: от 18 г. Лечение

Australia, Taiwan PharmaEngine NCT06973863

Набира участници Фаза 1

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Healthy Volunteers

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

Начало: 26.08.2025 Край: 01.09.2026 Възраст: 18–65 г. Лечение

Australia Suzhou Ribo Life Science Co. Ltd. NCT07042594

Набира участници Фаза 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation HER2- Negative Breast Cancer Hormone Receptor Positive Tumor Breast Cancer +2

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Начало: 26.08.2025 Край: 31.12.2031 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +14 Relay Therapeutics, Inc. NCT06982521

Набира участници Фаза 2

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

Obesity and Overweight

This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period

Начало: 25.08.2025 Край: 01.08.2026 Възраст: 18–75 г. Лечение

Australia Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. NCT07114419

Набира участници Фаза 1

IDOV-Immune for Advanced Solid Tumors

Colorectal Cancer Pancreatic Cancer Melanoma Ovarian Cancer +12

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.

Начало: 25.08.2025 Край: 31.05.2027 Възраст: от 18 г. Лечение

Australia, United States ViroMissile, Inc. NCT06910657

Набира участници

An International Observational Study of Adults With Acute Infection

Infectious Disease

Prospective, longitudinal studies of people with acute infections are essential to understand risk factors, clinical manifestations, pathobiology, and management strategies. Observational studies can provide data necessary to select interventions and strategies for testing in clinical trials and to develop key design features of trials. Observational studies can be particularly important for establishing an early knowledge base after emergence of a new pathogen, as illustrated by the recent emergence of influenza A (H1N1), SARS-CoV-2, and Mpox. This observational study protocol describes collection of data and biospecimens from sites across the world for characterizing acute infections in hospitalized patients. The protocol is designed to study respiratory infections, infections outside the respiratory tract, established infectious diseases, and emerging infectious diseases. Data generated in this study will be used to efficiently characterize acute infectious diseases and plan future clinical trials.

Начало: 25.08.2025 Край: 08.06.2027 Възраст: от 18 г.

Argentina, Australia, Brazil +13 University of Minnesota NCT07069400

Набира участници

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

Coronary Arterial Disease (CAD) de Novo Lesions in Native Coronary Arteries

AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.

Начало: 21.08.2025 Край: 01.03.2032 Възраст: от 18 г. Лечение

Australia, Germany, Ireland +3 Boston Scientific Corporation NCT06959524

Набира участници Фаза 1

Study of BHV-1300 in Graves' Disease

Graves Disease

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Начало: 21.08.2025 Край: 01.09.2026 Възраст: 18–65 г. Лечение

Australia, United States Biohaven Therapeutics Ltd. NCT06980649

Набира участници Фаза 1

A Study of YP05002 in Healthy Participants

Weight Management

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of YP05002 Tablets in healthy participants

Начало: 19.08.2025 Край: 30.06.2026 Възраст: 18–65 г. Лечение

Australia Yaopharma Co., Ltd. NCT07089823

Набира участници Фаза 1

A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

Chronic Hepatitis B Infection

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.

Начало: 19.08.2025 Край: 01.04.2027 Възраст: 18–55 г. Лечение

Australia Chimivac INC NCT07059403

Набира участници

The Ladera Suture-Mediated Large Bore Closure Study

Vascular Closure Femoral Arteriotomy Closure

This study evaluates the safety and performance of the Ladera Medical suture-mediated large bore closure (LBC) system in gaining post procedure hemostasis in subjects undergoing interventional catheterization procedures using a large-bore procedure sheath.

Начало: 18.08.2025 Край: 31.12.2025 Възраст: от 18 г. Лечение

Australia, Belgium, Netherlands Ladera Medical NCT06851481

Набира участници Фаза 1/2

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic

This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-day cycles.

Начало: 18.08.2025 Край: 01.07.2029 Възраст: от 18 г. Лечение

Australia, United States Amplia Therapeutics Limited NCT07026279

Набира участници Фаза 3

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

Начало: 18.08.2025 Край: 01.07.2028 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +8 Neurocrine Biosciences NCT07196501

Набира участници Фаза 3

PSMA PET Combined With MRI for the Detection of PCa

PCA Prostate Cancer Prostatic Neoplasm PSMA PET +5

This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

Начало: 18.08.2025 Край: 01.11.2026 Възраст: от 18 г. Диагностика

Australia Telix Pharmaceuticals (Innovations) Pty Limited NCT07052214

1 … 18 19 20 21 22 … 154